Biodel: Expecting Growth In Double Digits Through It's New Pipeline
Growth, Long/Short Equity, Momentum
Seeking Alpha Analyst Since 2013
Biodel (BIOD) has built a pipeline of insulin-based and other peptide hormone-based product candidates and companion products using proprietary formulation technology, scientific knowledge and clinical expertise in diabetes drug development.
This pipeline is expected to bring products to the market smoothly. The chart below accurately shows the projected growth by Biodel by 2020.
Biodel's proprietary drug-delivery technology is applicable to a wide range of peptides, proteins and other macromolecules. It allows us to alter the pharmacokinetic profile, route of administration and stability of drugs that otherwise would be impractical to use as therapeutics because they break down too rapidly.
This may have important implications for the use of insulin, a large molecule which is absorbed into the blood relatively slowly. Biodel's technology facilitates more natural and rapid absorption of recombinant human insulin than current insulin products and appears to improve its therapeutic efficacy in patients with Type 1 and Type 2 diabetes.
Clinical studies indicate that Biodel's lead ultra-rapid-acting insulin product candidate, BIOD-123, may be delivered into the bloodstream faster than regular human insulin and rapid-acting insulins.
In conclusion, Biodel is expected to see a rapid growth in the coming weeks and months as it is prepared to hit the market with its new products through its pipeline. In the coming weeks, the stock is expected to rise higher for it's strong sales and market growth.
Disclosure: I have no positions in any stocks mentioned, but may initiate a long position in BIOD over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.